Clinical Outcomes of Bio-Interventional Cyclodialysis with One or Multiple Allogeneic Reinforcements: A Multicenter Real-World Evidence Study
Ophthalmology and Therapy · 18.11.2026
DOI: 10.1007/s40123-026-01539-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 18.11.2026. Verfasst von Craig J Chaya und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Utah Health John A Moran Eye Center, Salt Lake City, UT, USA. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Bio-reinforced cyclodialysis uses a biocompatible acellular scleral allograft spacer to maintain a surgically created cleft and enhance uveoscleral outflow. The titratable effect of one vs two spacers on intraocular pressure (IOP) lowering has not previously been evaluated. Analysis of 260 eyes (187 patients) in the prospective, multicenter CREST study (NCT05506423) undergoing combined phacoemulsification and bio-reinforced cyclodialysis with one spacer ( N = 146) or two ( N = 114). The primary endpoint was IOP change from baseline to month 12. Analyses comprised unadjusted comparison, baseline-adjusted regression, 1:1 propensity score matching, doubly robust overlap weighting, and models accounting for enrolling site and fellow eyes. IOP after a secondary IOP-lowering procedure was censored. IOP reported as mean (95% CI) and medications as mean (± SD). At baseline, IOP was 17.8 (4.2) vs 18.5 (5.7) mmHg and medications 1.3 (1.1) vs 1.5 (1.4), with one vs two spacers, respectively. Enrolling site was most imbalanced: one center contributed 38.6% of two-spacer eyes but 7.5% of one-spacer eyes. The unadjusted difference in IOP reduction was 2.5 mmHg (1.2–3.8; p < 0.001) and persisted after propensity score matching (2.4 mmHg; 0.9–3.8; p = 0.001) and overlap weighting (2.0 mmHg; 1.2–2.8; p < 0.001). After accounting for site, it attenuated to 0.9 mmHg (− 0.1 to 1.8; p = 0.080), and to 0.4 mmHg (− 0.6 to 1.5; p = 0.424) using both strategies. Medication reduction (− 0.7 vs − 0.6; p = 0.643), freedom from secondary incisional surgery (98.6% vs 99.1%), and site-adjusted adverse event rates did not differ. Two-spacer treatment was associated with numerically greater 12-month IOP reduction in unadjusted and patient-level adjusted analyses, but this association was substantially attenuated after accounting for enrolling site. These short-term real-world data are compatible with, but do not establish, an independent incremental effect of a second spacer. Further study is warranted. ClinicalTrials.gov identifier NCT05506423.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Utah Health John A Moran Eye Center, Salt Lake City, UT, USA.
- New York Eye Surgery Center, New York, NY, USA.
- Cleveland Clinic Cole Eye Institute, Cleveland, OH, USA.
- Department of Ophthalmology, University of Buffalo, Buffalo, NY, USA.
- Eye Physicians and Surgeons of Arizona PC, Scottsdale, AZ, USA.
- New York Eye and Ear Infirmary of Mount Sinai, 310 East 14Th Street, New York, NY, 10003, USA. tianchul@yahoo.com.
Zitieren
APA
Chaya, C. J., Radcliffe, N. M., Qiu, M., Sieminski, S., Patel, S., Ianchulev, T., Ferreira, G., Shah, M., & Bacharach, J. (2026). Clinical Outcomes of Bio-Interventional Cyclodialysis with One or Multiple Allogeneic Reinforcements: A Multicenter Real-World Evidence Study. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-026-01539-2
Vancouver
Chaya CJ, Radcliffe NM, Qiu M, Sieminski S, Patel S, Ianchulev T, et al. Clinical Outcomes of Bio-Interventional Cyclodialysis with One or Multiple Allogeneic Reinforcements: A Multicenter Real-World Evidence Study. Ophthalmology and Therapy. 2026. doi:10.1007/s40123-026-01539-2
BibTeX
@article{Chaya2026,
author = {Chaya, Craig J and Radcliffe, Nathan M and Qiu, Mary and Sieminski, Sandra and Patel, Shamil and Ianchulev, Tsontcho and Ferreira, Gabriel and Shah, Manjool and Bacharach, Jason},
title = {Clinical Outcomes of Bio-Interventional Cyclodialysis with One or Multiple Allogeneic Reinforcements: A Multicenter Real-World Evidence Study},
journal = {Ophthalmology and Therapy},
year = {2026},
doi = {10.1007/s40123-026-01539-2}
}
EUVIMED